SCHEMBL29404563

SCHEMBL29404563

COc1ccc(F)cc1C(=O)NCc1ccc(C(=O)Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 2/20 0.60
▸ PTGER2 P43116 1/20 0.60
▸ PPARA Q07869 6/20 0.53
▸ PPARG P37231 2/20 0.53
▸ PPARD Q03181 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ GLA P06280 1/20 0.53
▸ NR1H4 Q96RI1 1/20 0.52
▸ CYP1A2 P05177 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ TSHR P16473 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ KMT2A Q03164 2/20 0.50
▸ CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24735199 1.00 PTGER4 (0.60) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL29404059 0.89 PTGER4 (0.74) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL31518952 0.89 PTGER4 (0.61) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL24735202 0.89 PTGER4 (0.61) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL24735197 0.89 PTGER4 (0.74) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL23042429 0.88 PPARA (0.64) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL26532908 0.85 PTGER4 (0.56) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL29471048 0.83 PTGER4 (0.54) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL25647135 0.83 PPARA (0.56) PTGER4PTGER2PPARAPPARGPPARD
SCHEMBL17339505 0.83 PTGER4 (0.54) PTGER4PTGER2PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211117-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE Loxo Oncology, Inc. (US) 2023-07-19 — — EP claimed
CN-116323553-A Processes and intermediates for preparing (S) -5-amino-3- (4- ((5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (1, 1-trifluoropropan-2-yl) -1H-pyrazole-4-carboxamide 罗索肿瘤学公司 2023-06-23 — — CN claimed
WO-2022056100-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE LOXO ONCOLOGY, INC. (US) 2022-03-17 — — WO claimed
EP-4501327-A2 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON S TYROSINEKINASE (BTK) DEGRADERS Accutar Biotechnology Inc. (US) 2025-02-05 — — EP disclosed
EP-4039688-B1 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS ACCUTAR BIOTECHNOLOGY INC (US) 2024-10-09 — — EP disclosed
EP-4211117-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE Loxo Oncology, Inc. (US) 2023-07-19 — — EP disclosed
CN-116323553-A Processes and intermediates for preparing (S) -5-amino-3- (4- ((5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (1, 1-trifluoropropan-2-yl) -1H-pyrazole-4-carboxamide 罗索肿瘤学公司 2023-06-23 — — CN disclosed
WO-2022169798-A2 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS ACCUTAR BIOTECHNOLOGY, INC. (US) 2022-08-11 — — WO disclosed
EP-4039688-A2 SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS Accutar Biotechnology Inc. (US) 2022-08-10 — — EP disclosed
WO-2022056100-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE LOXO ONCOLOGY, INC. (US) 2022-03-17 — — WO disclosed
Send feedback